PharmaMar Showcases New Data for YONDELIS® and PM1183 in Soft Tissue Sarcoma and Solid Tumors at ECCO 2015 .

MADRID, September 14, 2015 / PRNewswire .

•Final OS and subgroup analysis of the pivotal study SAR-3007 ( sponsored by Janssen Products ) .

•First interim results of the Y-IMAGE prospective study showing real-world data for trabectedin in advanced soft tissue sarcoma (STS)

•Clinical data of trabectedin in translocated-related sarcomas, and in advanced leiomyosarcomas and liposarcomas

•Early clinical studies of PM1183 in combination with paclitaxel or cisplatin show a synergistic activity .


PharmaMar announces that it will show new data from clinical pivotal studies as well as real-life data from prospective non-interventional studies to highlight the role of YONDELIS® (trabectedin) in STS, during the 18th ECCO - 40th ESMO European Cancer Congress, Vienna, 25 - 29 September 2015 (ECC 2015). This congress is the leading European forum for oncologists to keep abreast of practice-changing scientific studies and learning the most innovative approaches for cancer patient management. The abstracts have been selected for oral presentation and general poster presentation, and will feature data from the first-in-class drug YONDELIS® (trabectedin), and the transcription inhibitor PM1183 (lurbinectedin).

"Being part of this important oncology platform, as it is the European Cancer Congress, allows us to add to the clinical cancer community. We are glad we can present both clinical and real-life data for our compounds that will help clinicians and researchers, as they continue to seek new therapeutic avenues and improved treatments", says Nadia Badri, MD, VP Medical Affairs, PharmaMar. "PharmaMar is not only witnessing a major change in treatment approaches, but also contributing to this ongoing transformation."

...